Novavax to Present at the Ladenburg Thalmann 2015 Healthcare Conference

September 21, 2015

GAITHERSBURG, Md., Sept. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the Ladenburg Thalmann Healthcare 2015 Conference.

Conference details are as follows:

Date: Tuesday, September 29, 2015 Time: 1:30 – 1:55 p.m. US Eastern Time Location: Sofitel Hotel, New York City

Live webcast: http://wsw.com/webcast/ladenburg/nvax

The webcast and a replay of the presentation will also be accessible under the "Investors/Events" section of the Novavax website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-MTM adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

Contact:

Novavax, Inc.Barclay A. Phillips SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations

<u>ir@novavax.com</u> 240-268-2000

Russo Partners, LLCDavid SchullTodd Davenport, Ph.D.

 $\frac{\texttt{david.schull@russopartnersllc.comtodd.davenport@russopartnersllc.com}}{212-845-4271}$